APO Research
Talk to an analyst

APO RESEARCH · REPORT

Topoisomerase I Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Topoisomerase I Inhibitors Industry Research Report 2026

20 December 2025133 pages

Choose your research edition.

Industry ResearchTopoisomerase I Inhibitors Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Topoisomerase I Inhibitors Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Topoisomerase I Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Topoisomerase I Inhibitors Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Topoisomerase I Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Topoisomerase I Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Topoisomerase I Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Topoisomerase I Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Topoisomerase I Inhibitors include Chong Kun Dang Pharmaceutical, Grand Pharmaceutical, Teva Pharmaceutical Industries, CSPC Pharmaceutical, Novartis AG, Kelun Pharmaceutical, Pfizer, Hengrui Pharmaceuticals and Daiichi Sankyo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Topoisomerase I Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Topoisomerase I Inhibitors Market by Company

Chong Kun Dang Pharmaceutical

Grand Pharmaceutical

Teva Pharmaceutical Industries

CSPC Pharmaceutical

Novartis AG

Kelun Pharmaceutical

Pfizer

Hengrui Pharmaceuticals

Daiichi Sankyo

Yakult Honsha

Summit Medical

Servier Laboratories (Aust)

Nippon Kayaku

MOH Holdings

Meitheal Pharmaceuticals

Les Laboratoires Servier SAS

Ipsen SA

Eton Pharmaceuticals

Topoisomerase I Inhibitors Segment by Type

Camptothecin Derivatives

Non-camptothecin

Topoisomerase I Inhibitors Segment by Application

Hospital

Clinic

Others

Topoisomerase I Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topoisomerase I Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Topoisomerase I Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topoisomerase I Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Topoisomerase I Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Topoisomerase I Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Topoisomerase I Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Topoisomerase I Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Topoisomerase I Inhibitors Sales (k units) of Manufacturers (2021-2026) Table 7. Global Topoisomerase I Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Topoisomerase I Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Topoisomerase I Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Topoisomerase I Inhibitors Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Topoisomerase I Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Topoisomerase I Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Topoisomerase I Inhibitors, Product Type & Application Table 14. Global Topoisomerase I Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Topoisomerase I Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chong Kun Dang Pharmaceutical Company Information Table 19. Chong Kun Dang Pharmaceutical Business Overview Table 20. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 22. Chong Kun Dang Pharmaceutical Recent Developments Table 23. Grand Pharmaceutical Company Information Table 24. Grand Pharmaceutical Business Overview Table 25. Grand Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 27. Grand Pharmaceutical Recent Developments Table 28. Teva Pharmaceutical Industries Company Information Table 29. Teva Pharmaceutical Industries Business Overview Table 30. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio Table 32. Teva Pharmaceutical Industries Recent Developments Table 33. CSPC Pharmaceutical Company Information Table 34. CSPC Pharmaceutical Business Overview Table 35. CSPC Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 37. CSPC Pharmaceutical Recent Developments Table 38. Novartis AG Company Information Table 39. Novartis AG Business Overview Table 40. Novartis AG Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Novartis AG Topoisomerase I Inhibitors Product Portfolio Table 42. Novartis AG Recent Developments Table 43. Kelun Pharmaceutical Company Information Table 44. Kelun Pharmaceutical Business Overview Table 45. Kelun Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 47. Kelun Pharmaceutical Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Pfizer Topoisomerase I Inhibitors Product Portfolio Table 52. Pfizer Recent Developments Table 53. Hengrui Pharmaceuticals Company Information Table 54. Hengrui Pharmaceuticals Business Overview Table 55. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 57. Hengrui Pharmaceuticals Recent Developments Table 58. Daiichi Sankyo Company Information Table 59. Daiichi Sankyo Business Overview Table 60. Daiichi Sankyo Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio Table 62. Daiichi Sankyo Recent Developments Table 63. Yakult Honsha Company Information Table 64. Yakult Honsha Business Overview Table 65. Yakult Honsha Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Yakult Honsha Topoisomerase I Inhibitors Product Portfolio Table 67. Yakult Honsha Recent Developments Table 68. Summit Medical Company Information Table 69. Summit Medical Business Overview Table 70. Summit Medical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Summit Medical Topoisomerase I Inhibitors Product Portfolio Table 72. Summit Medical Recent Developments Table 73. Servier Laboratories (Aust) Company Information Table 74. Servier Laboratories (Aust) Business Overview Table 75. Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio Table 77. Servier Laboratories (Aust) Recent Developments Table 78. Nippon Kayaku Company Information Table 79. Nippon Kayaku Business Overview Table 80. Nippon Kayaku Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio Table 82. Nippon Kayaku Recent Developments Table 83. MOH Holdings Company Information Table 84. MOH Holdings Business Overview Table 85. MOH Holdings Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. MOH Holdings Topoisomerase I Inhibitors Product Portfolio Table 87. MOH Holdings Recent Developments Table 88. Meitheal Pharmaceuticals Company Information Table 89. Meitheal Pharmaceuticals Business Overview Table 90. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 92. Meitheal Pharmaceuticals Recent Developments Table 93. Les Laboratoires Servier SAS Company Information Table 94. Les Laboratoires Servier SAS Business Overview Table 95. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio Table 97. Les Laboratoires Servier SAS Recent Developments Table 98. Ipsen SA Company Information Table 99. Ipsen SA Business Overview Table 100. Ipsen SA Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Ipsen SA Topoisomerase I Inhibitors Product Portfolio Table 102. Ipsen SA Recent Developments Table 103. Eton Pharmaceuticals Company Information Table 104. Eton Pharmaceuticals Business Overview Table 105. Eton Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 107. Eton Pharmaceuticals Recent Developments Table 108. Global Topoisomerase I Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Topoisomerase I Inhibitors Sales by Region (2021-2026) & (k units) Table 110. Global Topoisomerase I Inhibitors Sales Market Share by Region (2021-2026) Table 111. Global Topoisomerase I Inhibitors Sales by Region (2027-2032) & (k units) Table 112. Global Topoisomerase I Inhibitors Sales Market Share by Region (2027-2032) Table 113. Global Topoisomerase I Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2021-2026) Table 115. Global Topoisomerase I Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2027-2032) Table 117. North America Topoisomerase I Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 119. North America Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 120. North America Topoisomerase I Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Topoisomerase I Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Topoisomerase I Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 124. Europe Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 125. Europe Topoisomerase I Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Topoisomerase I Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Topoisomerase I Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 129. Asia Pacific Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 130. Asia Pacific Topoisomerase I Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Topoisomerase I Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Topoisomerase I Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 134. South America Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 135. South America Topoisomerase I Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Topoisomerase I Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Topoisomerase I Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 139. Middle East and Africa Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 140. Middle East and Africa Topoisomerase I Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Topoisomerase I Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 143. Global Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 144. Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2026) Table 145. Global Topoisomerase I Inhibitors Sales Market Share by Type (2027-2032) Table 146. Global Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2026) Table 149. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2027-2032) Table 150. Global Topoisomerase I Inhibitors Price by Type (2021-2026) & (US$/unit) Table 151. Global Topoisomerase I Inhibitors Price by Type (2027-2032) & (US$/unit) Table 152. Global Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 153. Global Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 154. Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2026) Table 155. Global Topoisomerase I Inhibitors Sales Market Share by Application (2027-2032) Table 156. Global Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2026) Table 159. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2027-2032) Table 160. Global Topoisomerase I Inhibitors Price by Application (2021-2026) & (US$/unit) Table 161. Global Topoisomerase I Inhibitors Price by Application (2027-2032) & (US$/unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Topoisomerase I Inhibitors Distributors List Table 165. Topoisomerase I Inhibitors Customers List Table 166. Topoisomerase I Inhibitors Industry Trends Table 167. Topoisomerase I Inhibitors Industry Drivers Table 168. Topoisomerase I Inhibitors Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Topoisomerase I Inhibitors Product Image Figure 5. Global Topoisomerase I Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Topoisomerase I Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Topoisomerase I Inhibitors Sales (2021-2032) & (k units) Figure 8. Global Topoisomerase I Inhibitors Average Price (US$/unit) & (2021-2032) Figure 9. Camptothecin Derivatives Product Image Figure 10. Non-camptothecin Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Others Product Image Figure 14. Global Topoisomerase I Inhibitors Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Topoisomerase I Inhibitors, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Topoisomerase I Inhibitors Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Topoisomerase I Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Topoisomerase I Inhibitors Sales by Region in 2025 Figure 20. Global Topoisomerase I Inhibitors Revenue by Region in 2025 Figure 21. North America Topoisomerase I Inhibitors Market Size by Country in 2025 Figure 22. North America Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 23. North America Topoisomerase I Inhibitors Revenue Market Share by Country (2021-2032) Figure 24. United States Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Topoisomerase I Inhibitors Market Size by Country in 2025 Figure 28. Europe Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 29. Europe Topoisomerase I Inhibitors Revenue Market Share by Country (2021-2032) Figure 30. Germany Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Topoisomerase I Inhibitors Market Size by Country in 2025 Figure 41. Asia Pacific Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Topoisomerase I Inhibitors Revenue Market Share by Country (2021-2032) Figure 43. China Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Topoisomerase I Inhibitors Market Size by Country in 2025 Figure 52. South America Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 53. South America Topoisomerase I Inhibitors Revenue Market Share by Country (2021-2032) Figure 54. Brazil Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Topoisomerase I Inhibitors Market Size by Country in 2025 Figure 59. Middle East and Africa Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Topoisomerase I Inhibitors Revenue Market Share by Country (2021-2032) Figure 61. Egypt Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Topoisomerase I Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2032) Figure 67. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2032) Figure 68. Global Topoisomerase I Inhibitors Price (US$/unit) by Type (2021-2032) Figure 69. Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2032) Figure 70. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2032) Figure 71. Global Topoisomerase I Inhibitors Price (US$/unit) by Application (2021-2032) Figure 72. Topoisomerase I Inhibitors Value Chain Figure 73. Topoisomerase I Inhibitors Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Topoisomerase I Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Camptothecin Derivatives
  • Non-camptothecin
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chong Kun Dang Pharmaceutical
  • Grand Pharmaceutical
  • Teva Pharmaceutical Industries
  • CSPC Pharmaceutical
  • Novartis AG
  • Kelun Pharmaceutical
  • Pfizer
  • Hengrui Pharmaceuticals
  • Daiichi Sankyo
  • Yakult Honsha
  • Summit Medical
  • Servier Laboratories (Aust)
  • Nippon Kayaku
  • MOH Holdings
  • Meitheal Pharmaceuticals
  • Les Laboratoires Servier SAS
  • Ipsen SA
  • Eton Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Topoisomerase I Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Topoisomerase I Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Topoisomerase I Inhibitors Market Average Price (2021-2032)
  6. 2.3 Topoisomerase I Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Camptothecin Derivatives
  9. 2.3.3 Non-camptothecin
  10. 2.4 Topoisomerase I Inhibitors by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Topoisomerase I Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Topoisomerase I Inhibitors Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Topoisomerase I Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Topoisomerase I Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Topoisomerase I Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Topoisomerase I Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Topoisomerase I Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Topoisomerase I Inhibitors, Established Date
  9. 3.9 Global Topoisomerase I Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chong Kun Dang Pharmaceutical
  2. 4.1.1 Chong Kun Dang Pharmaceutical Company Information
  3. 4.1.2 Chong Kun Dang Pharmaceutical Business Overview
  4. 4.1.3 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  6. 4.1.5 Chong Kun Dang Pharmaceutical Recent Developments
  7. 4.2 Grand Pharmaceutical
  8. 4.2.1 Grand Pharmaceutical Company Information
  9. 4.2.2 Grand Pharmaceutical Business Overview
  10. 4.2.3 Grand Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  12. 4.2.5 Grand Pharmaceutical Recent Developments
  13. 4.3 Teva Pharmaceutical Industries
  14. 4.3.1 Teva Pharmaceutical Industries Company Information
  15. 4.3.2 Teva Pharmaceutical Industries Business Overview
  16. 4.3.3 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio
  18. 4.3.5 Teva Pharmaceutical Industries Recent Developments
  19. 4.4 CSPC Pharmaceutical
  20. 4.4.1 CSPC Pharmaceutical Company Information
  21. 4.4.2 CSPC Pharmaceutical Business Overview
  22. 4.4.3 CSPC Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  24. 4.4.5 CSPC Pharmaceutical Recent Developments
  25. 4.5 Novartis AG
  26. 4.5.1 Novartis AG Company Information
  27. 4.5.2 Novartis AG Business Overview
  28. 4.5.3 Novartis AG Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis AG Topoisomerase I Inhibitors Product Portfolio
  30. 4.5.5 Novartis AG Recent Developments
  31. 4.6 Kelun Pharmaceutical
  32. 4.6.1 Kelun Pharmaceutical Company Information
  33. 4.6.2 Kelun Pharmaceutical Business Overview
  34. 4.6.3 Kelun Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  36. 4.6.5 Kelun Pharmaceutical Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Topoisomerase I Inhibitors Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Hengrui Pharmaceuticals
  44. 4.8.1 Hengrui Pharmaceuticals Company Information
  45. 4.8.2 Hengrui Pharmaceuticals Business Overview
  46. 4.8.3 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  48. 4.8.5 Hengrui Pharmaceuticals Recent Developments
  49. 4.9 Daiichi Sankyo
  50. 4.9.1 Daiichi Sankyo Company Information
  51. 4.9.2 Daiichi Sankyo Business Overview
  52. 4.9.3 Daiichi Sankyo Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio
  54. 4.9.5 Daiichi Sankyo Recent Developments
  55. 4.10 Yakult Honsha
  56. 4.10.1 Yakult Honsha Company Information
  57. 4.10.2 Yakult Honsha Business Overview
  58. 4.10.3 Yakult Honsha Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Yakult Honsha Topoisomerase I Inhibitors Product Portfolio
  60. 4.10.5 Yakult Honsha Recent Developments
  61. 4.11 Summit Medical
  62. 4.11.1 Summit Medical Company Information
  63. 4.11.2 Summit Medical Business Overview
  64. 4.11.3 Summit Medical Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Summit Medical Topoisomerase I Inhibitors Product Portfolio
  66. 4.11.5 Summit Medical Recent Developments
  67. 4.12 Servier Laboratories (Aust)
  68. 4.12.1 Servier Laboratories (Aust) Company Information
  69. 4.12.2 Servier Laboratories (Aust) Business Overview
  70. 4.12.3 Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio
  72. 4.12.5 Servier Laboratories (Aust) Recent Developments
  73. 4.13 Nippon Kayaku
  74. 4.13.1 Nippon Kayaku Company Information
  75. 4.13.2 Nippon Kayaku Business Overview
  76. 4.13.3 Nippon Kayaku Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio
  78. 4.13.5 Nippon Kayaku Recent Developments
  79. 4.14 MOH Holdings
  80. 4.14.1 MOH Holdings Company Information
  81. 4.14.2 MOH Holdings Business Overview
  82. 4.14.3 MOH Holdings Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 MOH Holdings Topoisomerase I Inhibitors Product Portfolio
  84. 4.14.5 MOH Holdings Recent Developments
  85. 4.15 Meitheal Pharmaceuticals
  86. 4.15.1 Meitheal Pharmaceuticals Company Information
  87. 4.15.2 Meitheal Pharmaceuticals Business Overview
  88. 4.15.3 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  90. 4.15.5 Meitheal Pharmaceuticals Recent Developments
  91. 4.16 Les Laboratoires Servier SAS
  92. 4.16.1 Les Laboratoires Servier SAS Company Information
  93. 4.16.2 Les Laboratoires Servier SAS Business Overview
  94. 4.16.3 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio
  96. 4.16.5 Les Laboratoires Servier SAS Recent Developments
  97. 4.17 Ipsen SA
  98. 4.17.1 Ipsen SA Company Information
  99. 4.17.2 Ipsen SA Business Overview
  100. 4.17.3 Ipsen SA Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Ipsen SA Topoisomerase I Inhibitors Product Portfolio
  102. 4.17.5 Ipsen SA Recent Developments
  103. 4.18 Eton Pharmaceuticals
  104. 4.18.1 Eton Pharmaceuticals Company Information
  105. 4.18.2 Eton Pharmaceuticals Business Overview
  106. 4.18.3 Eton Pharmaceuticals Topoisomerase I Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  108. 4.18.5 Eton Pharmaceuticals Recent Developments
5 Global Topoisomerase I Inhibitors Market Scenario by Region
  1. 5.1 Global Topoisomerase I Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Topoisomerase I Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Topoisomerase I Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Topoisomerase I Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Topoisomerase I Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Topoisomerase I Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Topoisomerase I Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Topoisomerase I Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Topoisomerase I Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Topoisomerase I Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Topoisomerase I Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Topoisomerase I Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Topoisomerase I Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Topoisomerase I Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Topoisomerase I Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Topoisomerase I Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Topoisomerase I Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Topoisomerase I Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Topoisomerase I Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Topoisomerase I Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Topoisomerase I Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Topoisomerase I Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Topoisomerase I Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Topoisomerase I Inhibitors Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Topoisomerase I Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Topoisomerase I Inhibitors Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Topoisomerase I Inhibitors Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Topoisomerase I Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Topoisomerase I Inhibitors Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Topoisomerase I Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Topoisomerase I Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Topoisomerase I Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Topoisomerase I Inhibitors Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Topoisomerase I Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Topoisomerase I Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Topoisomerase I Inhibitors Value Chain Analysis
  2. 8.1.1 Topoisomerase I Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Topoisomerase I Inhibitors Production Mode & Process
  5. 8.2 Topoisomerase I Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Topoisomerase I Inhibitors Distributors
  8. 8.2.3 Topoisomerase I Inhibitors Customers
9 Global Topoisomerase I Inhibitors Analyzing Market Dynamics
  1. 9.1 Topoisomerase I Inhibitors Industry Trends
  2. 9.2 Topoisomerase I Inhibitors Industry Drivers
  3. 9.3 Topoisomerase I Inhibitors Industry Opportunities and Challenges
  4. 9.4 Topoisomerase I Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst